AR128418A1 - Inhibidores de la proteína tirosina fosfatasa y usos de estos - Google Patents
Inhibidores de la proteína tirosina fosfatasa y usos de estosInfo
- Publication number
- AR128418A1 AR128418A1 ARP230100235A ARP230100235A AR128418A1 AR 128418 A1 AR128418 A1 AR 128418A1 AR P230100235 A ARP230100235 A AR P230100235A AR P230100235 A ARP230100235 A AR P230100235A AR 128418 A1 AR128418 A1 AR 128418A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- heteroaryl
- aryl
- cycloalkyl
- Prior art date
Links
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 23
- 125000003118 aryl group Chemical group 0.000 abstract 21
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 21
- 125000001072 heteroaryl group Chemical group 0.000 abstract 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 10
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 10
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 10
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 229910052805 deuterium Inorganic materials 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- -1 lo) C1-C6 Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000005345 deuteroalkyl group Chemical group 0.000 abstract 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 abstract 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006697 (C1-C3) aminoalkyl group Chemical group 0.000 abstract 1
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305786P | 2022-02-02 | 2022-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128418A1 true AR128418A1 (es) | 2024-05-08 |
Family
ID=87552989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100235A AR128418A1 (es) | 2022-02-02 | 2023-02-01 | Inhibidores de la proteína tirosina fosfatasa y usos de estos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250136564A1 (https=) |
| EP (1) | EP4472976A4 (https=) |
| JP (1) | JP2025507292A (https=) |
| CN (1) | CN119137117A (https=) |
| AR (1) | AR128418A1 (https=) |
| TW (1) | TW202337459A (https=) |
| WO (1) | WO2023150535A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20240360A (es) * | 2022-02-02 | 2024-10-01 | Nerio Therapeutics Inc | Inhibidores de proteína tirosina fosfatasa y usos de estos |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2025030008A1 (en) * | 2023-08-02 | 2025-02-06 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitor combinations |
| CN120004876B (zh) * | 2023-11-16 | 2026-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| RU2015140066A (ru) * | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| PE20252767A1 (es) * | 2019-03-14 | 2025-12-22 | Calico Life Sciences Llc | Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos |
| CA3191842A1 (en) * | 2020-09-11 | 2022-03-17 | Calico Life Sciences Llc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| CN117279913A (zh) * | 2021-03-11 | 2023-12-22 | 金橘生物科技公司 | 杂环化合物及其用途 |
-
2023
- 2023-02-01 CN CN202380032050.5A patent/CN119137117A/zh active Pending
- 2023-02-01 US US18/834,761 patent/US20250136564A1/en active Pending
- 2023-02-01 EP EP23750344.6A patent/EP4472976A4/en active Pending
- 2023-02-01 TW TW112103529A patent/TW202337459A/zh unknown
- 2023-02-01 JP JP2024546071A patent/JP2025507292A/ja active Pending
- 2023-02-01 AR ARP230100235A patent/AR128418A1/es unknown
- 2023-02-01 WO PCT/US2023/061727 patent/WO2023150535A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4472976A1 (en) | 2024-12-11 |
| TW202337459A (zh) | 2023-10-01 |
| US20250136564A1 (en) | 2025-05-01 |
| JP2025507292A (ja) | 2025-03-18 |
| EP4472976A4 (en) | 2026-03-25 |
| WO2023150535A1 (en) | 2023-08-10 |
| CN119137117A (zh) | 2024-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128418A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| AR128417A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| PE20251071A1 (es) | Inhibidores de kras | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| AR129339A1 (es) | Inhibidores de parg | |
| AR089489A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| AR111281A1 (es) | Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| MD20210033A2 (ro) | Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| AR128669A1 (es) | INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS | |
| AR050963A1 (es) | Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres. | |
| AR127355A1 (es) | Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos | |
| AR107974A1 (es) | Análogos de nucleósidos alquinil como inhibidores de rinovirus humanos | |
| AR038094A1 (es) | Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |